Piramal Pharma Q1 Net Loss Narrows - Business News
By Rediff Money Desk, New Delhi Jul 26, 2024 13:40
Piramal Pharma Ltd reported a narrowed net loss of Rs 88.64 crore in Q1 FY24, driven by higher sales. Revenue stood at Rs 1,951.14 crore, compared to Rs 1,748.85 crore in the year-ago period.
New Delhi, Jul 26 (PTI) Piramal Pharma Ltd on Friday reported a narrowing of consolidated net loss at Rs 88.64 crore in the first quarter that ended June 30, 2024, on the back of higher sales.
The company had posted a consolidated net loss of Rs 98.58 crore in the same quarter last fiscal, Piramal Pharma said in a regulatory filing.
Consolidated revenue from operations in the quarter under review stood at Rs 1,951.14 crore as compared to Rs 1,748.85 crore in the year-ago period, the company added.
Total expenses in the first quarter were higher at Rs 2,038.16 crore as compared to Rs 1,908.66 crore in the same period a year ago.
"We have had a good start to the financial year with a steady all-round performance...," Piramal Pharma Chairperson Nandini Piramal said.
The company's CDMO (Contract Development and Manufacturing Organisation) business continues to witness sustained order inflows, especially for on-patent commercial manufacturing, she added.
"We are also seeing good demand for our differentiated offerings with an increase in customer enquiries and visits. In our CHG (Complex Hospital Generics) business, our planned expansion for inhalation anaesthesia portfolio is on track and is expected to get commercialised in FY26," Piramal said.
The company had posted a consolidated net loss of Rs 98.58 crore in the same quarter last fiscal, Piramal Pharma said in a regulatory filing.
Consolidated revenue from operations in the quarter under review stood at Rs 1,951.14 crore as compared to Rs 1,748.85 crore in the year-ago period, the company added.
Total expenses in the first quarter were higher at Rs 2,038.16 crore as compared to Rs 1,908.66 crore in the same period a year ago.
"We have had a good start to the financial year with a steady all-round performance...," Piramal Pharma Chairperson Nandini Piramal said.
The company's CDMO (Contract Development and Manufacturing Organisation) business continues to witness sustained order inflows, especially for on-patent commercial manufacturing, she added.
"We are also seeing good demand for our differentiated offerings with an increase in customer enquiries and visits. In our CHG (Complex Hospital Generics) business, our planned expansion for inhalation anaesthesia portfolio is on track and is expected to get commercialised in FY26," Piramal said.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 3.03 ( -4.72)
- 257560686
- Vodafone Idea L
- 15.98 (+ 5.13)
- 59360321
- Khoobsurat
- 1.87 (+ 4.47)
- 53562605
- Srestha Finvest
- 2.41 ( -1.23)
- 34944493
- NCL Research
- 1.02 ( -0.97)
- 27737245
MORE NEWS
ServiceNow Invests in Prodapt for AI Solutions
ServiceNow makes strategic investments in Prodapt to help clients adopt AI-enabled...
![India's Trade...](https://im.rediff.com/80-80/news/2018/dec/04india-china-trade.jpg)
India's Trade Deficit with China Narrowing: Goyal
India's trade deficit with China, while still high, has been narrowing in recent years....
![Indian Food...](https://im.rediff.com/80-80/money/2016/sep/13food.jpg)
Indian Food Exports Not Banned Due to...
The Indian government has confirmed that no country has banned Indian food product...